

Gomekli (mirdametinib)
Effective 04/01/2026

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	These medications have been designated specialty and must be filled through a contracted specialty pharmacy.		
Contact Information	Medical Benefit	Phone: 833-895-2611	Fax: 888-656-6671
	Pharmacy Benefit	Phone: 800-711-4555	Fax: 844-403-1029
Exceptions	N/A		

Overview

Gomekli (mirademetinib) is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromatosis (PN) not amenable to complete resection.

Koselguo (selumetinib) is another kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic inoperable plexiform neurofibromas (PN).

Coverage Guidelines

Authorization may be granted for members new to the plan within the past 90 days who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs

OR

Authorization may be granted when all of the following criteria are met:

1. Diagnosis of neurofibromatosis type 1 (NF1)
2. Member has symptomatic plexiform neurofibromas (PN) not amenable to resection
3. Member has had an inadequate response, adverse reaction, or contraindication to Koselugo
4. Member will not use the requested medication in combination with Koselugo

Continuation of Therapy

Requests for reauthorization will be approved when the following criteria are met:

1. Member has not experienced disease progression or unacceptable toxicity while on the requested medication.
2. Member will not use the requested medication in combination with Koselugo.

Limitations

1. Initial approvals and reauthorizations will be approved for 12 months.
2. The following quantity limitations apply:

Drug Name and Dosage Form	Quantity Limit
Gomekli 1mg tablet for suspension	168 tablets per 28 days

Gomekli 1 mg capsule	42 capsules per 28 days
Gomekli 2 mg capsule	84 capsules per 28 days

References

1. Gomekli (mirdametinib) [prescribing information]. Stamford, CT: SpringWorks Therapeutics, Inc.; February 2025.
2. Koselugo (selumetinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals, LP; January 2024.

Review History

06/11/2025 – Reviewed at June P&T. Effective 09/01/2025.

12/10/2025 – Reviewed and updated at December P&T. Updated criteria to reflect Koselugo’s updated age indication, requiring trial and failure with Koselugo for all members. Effective 04/01/2026.

